Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
Akili, Inc. (Nasdaq: AKLI) announced its participation in the Biotech Showcase and Solebury 1x1 Management Access Conference, scheduled for January 11 in San Francisco.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BOSTON--(BUSINESS WIRE)--
Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongside the J.P. Morgan Healthcare Conference in San Francisco next week.
Company leaders will also meet with investors attending the J.P. Morgan Healthcare Conference.
About Akili
Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.